Purpose: This study evaluated the efficacy and safety of a multimodal conservative regimen, oral baclofen plus pelvic-floor muscle training (PFMT), in young adult male patients (18-40 years) with dysfunctional voiding (DV) diagnosed according to International Continence Society criteria on video-urodynamic studies (vUDS). Study Design: This was a single-center, single-arm, retrospective observational study conducted at a tertiary-care academic hospital. Methods: Between January 2022 and January 2025, all young male patients (18-40 years) diagnosed with DV on vUDS were enrolled (n = 50) and treated with oral baclofen (10 mg 3 times daily) and PFMT. Symptom scores (International Prostate Symptom Score IPSS, Urogenital Distress Inventory-6 UDI-6) were recorded at baseline and 2, 4, and 6 weeks, and at 6 months, whereas uroflowmetry parameters (maximum flow rate Qmax, average flow rate Qavg, postvoid residual PVR) were recorded at baseline and 6 months of follow-up to assess treatment efficacy. Results: Significant improvement occurred by 6 months: The mean IPSS decreased from 20.1 ± 5.3 to 15.6 ± 4.8 ( P < .001) and UDI-6 from 23.5 ± 6.2 to 17.6 ± 5.9 ( P < .001). Qavg increased from 6.37 ± 2.1 to 8.12 ± 2.3 ml/s ( P < .001); changes in Qmax and PVR were not statistically significant. No major adverse events observed. Conclusion: Multimodal conservative therapy combining baclofen (10 mg 3 times daily) and PFMT significantly improves subjective symptom scores and urinary flow dynamics in young adult male patients with DV. Future randomized studies are warranted to validate these findings.
Mittal et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: